Aiqi official website shows that Qin Hao Pharmaceutical (Suzhou) Co., Ltd. was listed on February 14, 2022. On February 4th, 2022, Qin Hao Pharmaceutical (Suzhou) Co., Ltd., a new generation of anti-tumor small molecule drug research and development enterprise, has completed the series B financing of several hundred million yuan. Qin Hao Pharmaceutical Co., Ltd. is an innovative biomedical company facing the world, focusing on the research and development of original small molecule anti-tumor drugs. Headquartered in Suzhou Industrial Park, it has established a research and development team of 100 people. At the same time, four new drug research and development centers, namely, innovation research center, drug design and discovery center, new drug screening and evaluation center and clinical development center, have been built, and more than 10 product pipelines have been built.